Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as
induction therapy. After 6 cycles, maintenance rituximab may be administered per physician
discretion.
Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2
(BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with
mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This
may help to slow down the growth of cancer or may cause cancer cells to die.
The purpose of this study is to see if venetoclax in combination with bendamustine and
rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to
examine the side effects, good and bad, associated with this combination.